Abstract:
Cytokine Release Syndrome (CRS) is a severe and potentially life-threatening side effect of immunotherapies, including T Cell Bispecific Antibodies (TCBs). CRS is characterized by the rapid and excessive release of pro-inflammatory cytokines, leading to systemic inflammatory response and organ damage. Understanding the mechanisms underlying CRS is crucial for developing effective strategies to prevent and manage this complication. In this review, we will discuss the current knowledge on the pathophysiology of CRS induced by TCBs, focusing on the key players involved in cytokine production and release, as well as the factors influencing CRS severity. We will also explore potential therapeutic interventions targeting these mechanisms to mitigate CRS and improve patient outcomes.
Introduction:
T Cell Bispecific Antibodies (TCBs) are a promising class of immunotherapies that engage T cells and redirect their cytotoxic activity towards cancer cells. TCBs have shown remarkable efficacy in treating various hematological malignancies and solid tumors. However, their use is associated with a significant risk of developing CRS, which can limit their clinical utility.
Pathophysiology of CRS induced by TCBs:
The onset of CRS following TCB therapy is believed to be triggered by the activation of T cells and subsequent dysregulation of the immune response. TCBs bind to both tumor cells and T cells, leading to T cell activation and proliferation. Activated T cells produce and release a variety of pro-inflammatory cytokines, including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interferon-gamma (IFN-γ). These cytokines then trigger a cascade of events, resulting in the production of additional cytokines and amplification of the inflammatory response.
Key players in CRS:
Several cell types and signaling pathways contribute to the development of CRS. Tumor cells, antigen-presenting cells (APCs), and endothelial cells play a role in initiating and perpetuating the inflammatory response. Activated T cells produce cytokines, such as IL-6, that further activate APCs and promote the release of additional pro-inflammatory cytokines. Endothelial cells also contribute to CRS by upregulating adhesion molecules and promoting leukocyte infiltration into tissues. Moreover, the dysregulated production of cytokines is influenced by various factors, including the tumor burden, T cell activation state, and genetic background of the patient.
Therapeutic interventions for CRS:
Managing CRS requires a multidisciplinary approach aimed at controlling the immune response and mitigating cytokine-mediated toxicity. Corticosteroids are commonly used to suppress inflammation and modulate immune cell activity. However, their efficacy in preventing or treating CRS remains controversial. Other potential interventions include targeting specific cytokines or downstream signaling pathways involved in CRS pathogenesis. For example, tocilizumab, an IL-6 receptor antagonist, has shown promise in reducing CRS severity. Additionally, strategies to enhance T cell activation selectivity and limit cytokine release are being explored.
Conclusion:
CRS is a significant challenge associated with TCB therapy. Understanding the mechanisms underlying CRS will facilitate the development of targeted interventions to prevent and manage this complication. Further research is needed to unravel the complexities of CRS pathophysiology and identify novel therapeutic approaches that improve patient outcomes. |
求助已关闭
30